Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
Go back to Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001| (NASDAQ: ETON) | Delayed: 58.45 -1.45 (2.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.90 | 52 Week High | $ | |||
| Open | $59.87 | 52 Week Low | $ | |||
| Day High | $59.95 | P/E | N/A | |||
| Day Low | $56.93 | EPS | $ | |||
| Volume | 521,574 | |||||

